On April 9, 2014, Clinipace Worldwide, a global digital clinical research organization (dCRO), announced that Karyopharm Therapeutics Inc. (NASDAQ:KPTI), has entered into a preferred provider agreement with Clinipace to manage several clinical programs, including oncology, wound healing, and other diseases. Karyopharm Therapeutics Inc (NASDAQ:KPTI), shares after opening at $33.33 moved to $37.23 on last trade day and at the end of the day closed at $36.79. Company price to sales ratio in past twelve months was calculated as 2736.26 and price to cash ratio as 7.02. Karyopharm Therapeutics Inc (NASDAQ:KPTI), showed a negative weekly performance of 13.80%.
Avanir Pharmaceuticals Inc (NASDAQ:AVNR) announced in the last week of March that its new drug application for its drug candidate AVP-825 has been accepted by the U.S Food and Drug Administration. The drug candidate has been tested for its effectiveness to treat recurring migraine. Avanir Pharmaceuticals Inc (NASDAQ:AVNR), shares advanced 3.87% in last trading session and ended the day on $8.40. Avanir Pharmaceuticals Inc (NASDAQ:AVNR), return on equity ratio is recorded as -362.80% and its return on assets is -99.70%. Avanir Pharmaceuticals Inc (NASDAQ:AVNR), yearly performance is 34.84%.
Investors eyeing a purchase of Horizon Pharma Inc (NASDAQ:HZNP) shares, but cautious about paying the going market price of $14.06/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the November put at the $10 strike, which has a bid at the time of this writing of $1.20. Collecting that bid as the premium represents a 12% return against the $10 commitment, or a 19.1% annualized rate of return. Horizon Pharma Inc (NASDAQ:HZNP), shares moved up 6.39% in last trading session and was closed at $14.31, while trading in range of $13.48 – $14.45. Horizon Pharma Inc (NASDAQ:HZNP), year to date (YTD) performance is 87.80%.
Rigel Pharmaceuticals Inc.’s 50-day moving average of $3.46 is above the 200-day moving average of $3.38. Additionally, shares of the company are trading at the Relative Strength Index (RSI) of 62.85. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), weekly performance is -7.61%. On last trading day company shares ended up $3.52. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), distance from 50-day simple moving average (SMA50) is -4.50%. Analysts mean target Price for the company is $5.75.